Synta Announces Upcoming Presentations at the 15th World Conference on Lung Cancer
Webcast and conference call scheduled for
“Randomized Phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients”
Abstract #: O03.01
Session: Oral Abstract Session, NSCLC – Targeted
Therapies I
Date and time:
Location: Bayside Auditorium B, Level 1
Presenter:
Suresh Ramalingam, M.D.,
Results will be presented from the analysis planned for one year from
the last patient enrolled in the 253-patient primary enrollment phase of
GALAXY-1. The Company expects to release these results on
Based upon the number of overall survival events, Synta expects that the final overall survival analysis of GALAXY-1 will be conducted by early 2014.
Other presentations
Additional ganetespib presentations at the WCLC include:
“Antimetastatic activity of ganetespib: preclinical studies and assessment of new lesion growth in the GALAXY-1 NSCLC trial”
Abstract #: P1.01-007
Session: Poster Session 1 – Cancer Biology
Date
and Time:
Location:
Exhibit Hall, Ground Level
Presenter: Vojo Vukovic, M.D., Ph.D.,
“Novel mechanisms of sensitivity and acquired resistance to Hsp90 inhibition by ganetespib”
Abstract #: MO12.01
Session: Prognostic and Predictive Biomarkers
III
Date and Time:
Location: Parkside Ballroom B, Level 1
Presenter: Sara
Busacca, Ph.D.,
Conference call
Synta will host a webcast and conference call at
The webcast,
which will include both audio and slides, can be accessed by visiting
the home
page or the Investor
Relations section of the
The conference call can be accessed by dialing (877) 407-8035 (U.S.) or
(201) 689-8035 (International). Participants can follow along with a
prepared slide presentation that will be available on the home page of
the company’s website, www.syntapharma.com.
For those unable to join the live call, a replay will be available from
About Ganetespib
Ganetespib, an investigational drug candidate, is a selective inhibitor
of heat shock protein 90 (Hsp90), a molecular chaperone which controls
the folding and activation of a number of client proteins that drive
tumor development and progression. Many solid and hematologic tumors are
dependent on Hsp90 client proteins including proteins involved in
“oncogene addiction” (ALK, HER2, mutant BRAF and EGFR, androgen
receptor, estrogen receptor, JAK2); proteins involved in resistance to
chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1,
survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha,
VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF,
AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of
Hsp90 by ganetespib results in the inactivation, destabilization, and
eventual degradation of these cancer-promoting proteins. Ganetespib is
being evaluated in trials in lung cancer, breast cancer, and other tumor
types. The most common adverse event seen to date has been transient,
mild or moderate diarrhea, which has been manageable with standard
supportive care. Information on these trials can be found at www.clinicaltrials.gov.
Ganetespib has received Fast Track designation from
About the GALAXY Program
The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program consists of two randomized trials comparing the combination of ganetespib and docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient population most likely to derive benefit from ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More information about the GALAXY trials can be found at www.clinicaltrials.gov (NCT01348126 and NCT01798485).
About Lung Cancer
Lung cancer is the leading cause of cancer-related death in the world,
accounting for nearly 1.4 million deaths in 2008, according to the
About
Safe Harbor Statement
This media release may contain forward-looking statements about
Source:
Investor Relations Contact:
Synta Pharmaceuticals Corp.
George
Farmer, 781-541-7213
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media
Contact:
Argot Partners
Eliza Schleifstein, 973-361-1546
[email protected]